Complete financial analysis of Vivos Inc. (RDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivos Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- AmTRAN Technology Co.,Ltd (2489.TW) Income Statement Analysis – Financial Results
- Sundaram Finance Holdings Limited (SUNDARMHLD.NS) Income Statement Analysis – Financial Results
- Blue Jet Healthcare Limited (BLUEJET.NS) Income Statement Analysis – Financial Results
- Xcelerate Inc. (XCRT) Income Statement Analysis – Financial Results
- Meier Tobler Group AG (0QQK.L) Income Statement Analysis – Financial Results
Vivos Inc. (RDGL)
About Vivos Inc.
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.50K | 36.50K | 14.89K | 7.00K | 9.50K | 0.00 | 4.05K | 8.11K | 24.11K | 24.11K | 140.60K | 247.97K | 393.60K | 360.61K | 320.36K | 268.24K | 130.06K |
| Cost of Revenue | 25.54K | 28.78K | 12.00K | 5.61K | 6.03K | 0.00 | 1.47K | 2.95K | 474.00 | 1.10K | 105.33K | 72.82K | 64.04K | 70.13K | 125.69K | 155.46K | 55.84K |
| Gross Profit | -6.04K | 7.72K | 2.89K | 1.39K | 3.47K | 0.00 | 2.58K | 5.16K | 23.63K | 23.00K | 35.27K | 175.15K | 329.56K | 290.48K | 194.68K | 112.79K | 74.21K |
| Gross Profit Ratio | -30.95% | 21.15% | 19.39% | 19.89% | 36.55% | 0.00% | 63.67% | 63.65% | 98.03% | 95.42% | 25.09% | 70.63% | 83.73% | 80.55% | 60.77% | 42.05% | 57.06% |
| Research & Development | 732.70K | 343.80K | 286.85K | 84.67K | 67.58K | 104.21K | 203.04K | 328.03K | 149.65K | 44.27K | 416.16K | 973.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.77M | 2.18M | 2.22M | 589.25K | 1.27M | 2.37M | 2.30M | 3.83M | 2.45M | 1.96M | 3.40M | 5.54M | 2.22M | 2.89M | 1.70M | 2.37M | 933.95K |
| Selling & Marketing | 281.72K | 0.00 | 0.00 | 0.00 | 0.00 | 11.50K | 111.66K | 284.14K | 0.00 | 1.30K | 9.91K | 18.31K | 58.88K | 29.07K | 6.63K | 39.35K | 2.39K |
| SG&A | 2.05M | 2.18M | 2.22M | 589.25K | 1.27M | 2.39M | 2.42M | 4.11M | 2.45M | 1.97M | 3.41M | 5.56M | 2.28M | 2.92M | 1.70M | 2.41M | 936.33K |
| Other Expenses | 0.00 | 0.00 | 2.50M | 3.00K | 0.00 | -17.58K | -575.01K | 2.95K | 5.67K | 11.99K | 208.63K | 483.20K | 609.99K | 945.73K | 1.04M | 3.65M | 1.73M |
| Operating Expenses | 2.79M | 2.53M | 2.50M | 673.91K | 1.33M | 2.47M | 2.62M | 4.44M | 2.60M | 1.98M | 3.61M | 6.05M | 2.89M | 3.87M | 2.74M | 6.05M | 2.66M |
| Cost & Expenses | 2.81M | 2.55M | 2.52M | 679.52K | 1.34M | 2.47M | 2.62M | 4.44M | 2.60M | 1.98M | 3.72M | 6.12M | 2.96M | 3.94M | 2.87M | 6.21M | 2.72M |
| Interest Income | 49.58K | 0.00 | 25.38K | 287.47K | 261.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 599.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 25.38K | 287.47K | 261.37K | 5.65M | 3.90M | 6.26M | 2.66M | 2.46M | 1.60M | 1.10M | 408.47K | 860.25K | 839.63K | 219.45K | 238.98K |
| Depreciation & Amortization | 0.00 | 2.52M | 2.50M | 672.52K | 1.33M | 1.47K | 1.47K | 2.95K | 5.67K | 11.99K | 208.63K | 483.20K | 546.39K | 545.19K | 562.67K | 1.53M | 1.16M |
| EBITDA | -2.79M | 0.00 | -2.50M | -669.52K | -18.74K | -2.49M | -2.51M | -3.59M | 8.90M | -15.64M | -1.66M | -7.00M | -1.79M | -2.65M | -2.59M | -4.41M | -1.47M |
| EBITDA Ratio | -14,323.83% | -6,898.13% | -16,805.25% | -9,564.59% | -13,999.78% | 0.00% | -64,515.07% | -54,680.85% | -10,668.40% | -8,059.69% | -2,397.52% | -2,172.66% | -512.06% | -945.64% | -432.09% | -1,643.33% | -1,101.27% |
| Operating Income | -2.79M | -2.52M | -2.50M | -672.52K | -1.33M | -2.49M | -2.62M | -4.44M | -2.58M | -1.96M | -3.58M | -5.87M | -2.56M | -3.73M | -2.55M | -5.94M | -2.59M |
| Operating Income Ratio | -14,323.83% | -6,898.13% | -16,805.25% | -9,607.44% | -13,999.78% | 0.00% | -64,551.41% | -54,717.19% | -10,691.93% | -8,109.43% | -2,545.90% | -2,367.52% | -650.88% | -1,033.06% | -795.86% | -2,214.16% | -1,991.78% |
| Total Other Income/Expenses | -101.61K | 47.59K | -25.97K | -284.47K | -280.12K | -5.21M | -3.80M | -5.42M | 8.27M | -16.15M | 108.81K | -2.72M | -187.75K | -329.69K | -1.44M | -374.91K | -278.98K |
| Income Before Tax | -2.89M | -2.47M | -2.53M | -956.99K | -1.61M | -7.70M | -6.42M | -9.85M | 6.23M | -18.11M | -3.47M | -8.59M | -2.75M | -4.06M | -3.99M | -6.16M | -2.87M |
| Income Before Tax Ratio | -14,844.89% | -6,767.75% | -16,979.69% | -13,671.31% | -16,948.39% | 0.00% | -158,330.71% | -121,545.33% | 25,853.19% | -75,114.92% | -2,468.52% | -3,462.65% | -698.58% | -1,124.48% | -1,246.08% | -2,295.97% | -2,206.29% |
| Income Tax Expense | 0.00 | -47.59K | 25.38K | 287.47K | 261.37K | 5.21M | 3.90M | 6.26M | 2.66M | 2.46M | 1.60M | 1.10M | 408.47K | 479.69K | 1.44M | 0.00 | 238.98K |
| Net Income | -2.89M | -2.42M | -2.55M | -1.24M | -1.87M | -7.70M | -6.42M | -9.85M | 6.23M | -18.11M | -3.47M | -8.59M | -2.75M | -4.06M | -3.99M | -6.16M | -2.87M |
| Net Income Ratio | -14,844.89% | -6,637.37% | -17,150.14% | -17,778.04% | -19,699.69% | 0.00% | -158,330.71% | -121,545.33% | 25,853.19% | -75,114.92% | -2,468.52% | -3,462.65% | -698.58% | -1,124.48% | -1,246.08% | -2,295.97% | -2,206.29% |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 | -1.06 | -3.67 | 2.72 | -45.38 | -27.58 | -90.77 | -31.72 | -57.75 | -66.30 | -141.80 | -79.86 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 | -1.06 | -3.67 | 2.72 | -45.38 | -27.58 | -90.77 | -31.72 | -57.75 | -66.30 | -141.80 | -79.86 |
| Weighted Avg Shares Out | 368.81M | 351.43M | 325.85M | 222.80M | 175.20M | 55.50M | 6.05M | 2.69M | 2.31M | 399.09K | 125.86K | 94.59K | 86.69K | 70.22K | 60.21K | 43.43K | 35.93K |
| Weighted Avg Shares Out (Dil) | 368.81M | 351.43M | 325.85M | 222.80M | 175.20M | 55.50M | 6.05M | 2.69M | 2.31M | 399.09K | 125.86K | 94.59K | 86.69K | 70.22K | 60.21K | 43.43K | 35.93K |
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
LITTLETON, Colo., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders...
Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA
Richland WA, July 29, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Provides IDE Submission Status Update
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Richland WA, June 28, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
Vivos Therapeutics reports positive results from pilot of provider-based model
Vivos Therapeutics (NASDAQ:VVOS) has announced positive results from a seven-month, multi-site pilot of its new provider-based marketing and distribution model. The medical technology firm on June 12, 2024, unveiled its new marketing and distribution model under which it seeks to...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos' Flagship CARE Oral Medical Devices 5 to 1 Over Traditional Oral Appliances 8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance...
Vivos Therapeutics announces strategic alliance and $7.5M investment
Vivos Therapeutics (NASDAQ:VVOS) announced a strategic marketing and distribution alliance with a multi-center sleep testing and treatment operator in Colorado. In a statement, Vivos said that the alliance marks a shift in Vivos' approach to distributing its advanced obstructive sleep...
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos' Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit
3 Stocks to Turn $1,000 Into $1 Million: February 2024
If you want millionaire-maker stocks, go consult Warren Buffett. The Oracle of Omaha has plenty of compelling ideas.
High-Risk, High-Reward: 7 OTC Stocks That Could Make You Rich This Year
I cannot stress enough how risky OTC stocks or securities traded over the counter really are. For one thing, just the name OTC should ring some alarm bells.
Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA's...
Source: https://incomestatements.info
Category: Stock Reports